---
document_datetime: 2024-09-30 14:16:11
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dificlir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dificlir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.5438699
conversion_datetime: 2025-12-21 16:42:08.221791
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dificlir

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0055              | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier | 05/08/2024                          | n/a                                         |                                  |           |
| IB/0054/G            | This was an application for a group of variations.                                                                          | 28/06/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                  |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0053            | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                              | 20/06/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| PSUSA/1390/ 202305 | Periodic Safety Update EU Single assessment - fidaxomicin                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/01/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0052/G          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                     | 15/11/2023 | 01/12/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0049            | Update of section 4.2 and 5.1 of the SmPC in order to introduce information a new posology regimen based on final results from EXTEND study - A Phase IIIb/IV Randomized, Controlled, Open-Label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium difficile Infection in an Older Population. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 10/11/2022 | 12/12/2022 | SmPC and PL            | Based on the EXTEND study, a phase 3b/4 study that evaluated the efficacy of Extended pulsed fidaxomicin (EPFX) in the treatment of Clostridioides difficile infections (CDI) in male and female patients aged 60 years and older compared with standard vancomycin therapy, language on extended pulse dosing regimen (200 mg (one tablet) administered twice daily (once every 12 hours) for 5 days, and then every other day for a further 20 days (10 tablets) was introduced in Section 4.2 and 5.1 of the SmPC and section 3 of the Dificlir PL. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|             | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                 | Product Characteristics.   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------|
| IB/0050/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 14/10/2022 | n/a        |                 |                            |
| IAIN/0048   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                     | 07/03/2022 | 24/06/2022 | Annex II and PL |                            |
| IB/0046     | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/10/2021 | n/a        |                 |                            |
| IAIN/0045/G | This was an application for a group of variations. Replacement or addition of a manufacturer responsible for importation and/or batch release.                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 19/05/2021 | 24/06/2022 | Annex II and PL |                            |

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch   |            |            |                        |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| T/0044             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/02/2021 | 09/03/2021 | SmPC, Labelling and PL |                                   |
| PSUSA/1390/ 202005 | Periodic Safety Update EU Single assessment - fidaxomicin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/01/2021 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0043/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/12/2020 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|             | - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |                 | B.II.d.2.a   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------|
| IA/0042     | B.I.c.z - Container closure system of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/12/2020 | n/a        |                 |              |
| IAIN/0041/G | This was an application for a group of variations. B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                             | 30/11/2020 | 09/03/2021 | Annex II and PL |              |
| IA/0039     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                                                                                              | 07/08/2020 | n/a        |                 |              |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                                  |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------|
| IA/0038/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 29/06/2020 | n/a        |                                  | an obsolete parameter) |
| X/0034/G  | This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                         | 12/12/2019 | 13/02/2020 | SmPC, Annex II, Labelling and PL |                        |
| IA/0037/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/12/2019 | n/a        |                                  |                        |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0036/G | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                      | 08/05/2019 | n/a |
| IA/0035   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/04/2019 | n/a |
| II/0033   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated                                                                                                                                                                                                                                                                                                                                                                                                                                     | 31/10/2018 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0032/G          | This was an application for a group of variations. Update of sections 4.4 and 5.2 of the SmPC in order to update the safety information based on results from the PROFILE study, an open label study designed to evaluate the pharmacokinetics of fidaxomicin in IBD subjects with CD. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 9.0 has also been submitted. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 17/05/2018 | 19/07/2018 | SmPC and PL         | The warning section of the SmPC is updated to reflect that there is data available on patients with concomitant inflammatory bowel disease (IBD). These data indicates no major difference in plasma concentrations of fidaxomicin or its main metabolite in patients with IBD as compared with patients without IBD in other studies. The maximum fidaxomicin levels in CDI patients with concomitant IBD were within the range of levels found in CDI patients without IBD. |
| PSUSA/1390/ 201705 | Periodic Safety Update EU Single assessment - fidaxomicin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 11/01/2018 | n/a        |                     | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0030            | B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 03/08/2017 | 19/07/2018 | SmPC, Labelling and |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                    | container without a complete deletion of a strength or pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            | PL                        |                                                                                                                                                                                                                                                                                       |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028            | C.I.11: Updated RMP version 8 in order to remove the post-authorization measure (PAM) MEA003 (concerning clinical study 2819-CL-2001 in patients with Clostridium difficile Infection who will receive a second course of fidaxomicin) due to the non- feasibility of the study. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH | 20/07/2017 | n/a        |                           | The limited feasibility to perform the MEA 003 and also to retrospectively collect data from patients with at least two courses of fidaxomicin it is acknowledged. It is also considered appropriate to conclude the ClosER study as planned. The updated RMP version 8 was approved. |
| IB/0029/G          | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                     | 26/04/2017 | n/a        |                           |                                                                                                                                                                                                                                                                                       |
| PSUSA/1390/ 201605 | Periodic Safety Update EU Single assessment - fidaxomicin                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/01/2017 | n/a        |                           | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                     |
| R/0026             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/06/2016 | 22/08/2016 | SmPC, Annex II, Labelling |                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                  |            |            | and PL      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0025            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                       | 09/12/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/1390/ 201505 | Periodic Safety Update EU Single assessment - fidaxomicin                                                                                                                                                                                                                                                                        | 03/12/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0022            | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                           | 25/06/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/1390/ 201411 | Periodic Safety Update EU Single assessment - fidaxomicin                                                                                                                                                                                                                                                                        | 11/06/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0021            | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                              | 26/02/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUV/0020          | Periodic Safety Update                                                                                                                                                                                                                                                                                                           | 04/12/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0016            | Update of of sections 4.5 and 5.2 of the SmPC with the results from study 2819-CL-2003, assessing the effect of multiple doses of fidaxomicin on the pharmacokinetics of a single dose of rosuvastatin in healthy male subjects. In addition, the local representatives for Estonia, Lithuania and Latvia are updated in the PL. | 26/06/2014 | 28/05/2015 | SmPC and PL | The potential drug drug interaction between fidaxomicin and rosuvastatin was investigated in study 2819-CL-2003, an open-label, randomized, two-way crossover study in healthy male subjects following multiple oral doses of fidaxomicin and a single oral dose of rosuvastatin. The study demonstrated that fidaxomicin does not have a clinically significant effect on the exposure of rosuvastatin. The Sections 4.5 and 5.2 of the SmPC were updated in line |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             | with these results. The RMP was updated accordingly. The CHMP concluded that these results do not affect the overall benefit/risk balance for Dificlir, which remains positive.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0019/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 20/06/2014 | n/a        |             |                                                                                                                                                                                   |
| PSUV/0017 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/06/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                 |
| PSUV/0015 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/01/2014 | 21/03/2014 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0015.                                                 |
| IAIN/0018 | C.I.8.a - Introduction of or changes to a summary of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/03/2014 | n/a        |             |                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|             | Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0014/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                                                                                                                                                                                                                                      | 25/09/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0013     | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/07/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0011     | Update of sections 4.4 and 4.8 of the SmPC to add a warning on angioedema and hypersensitivity reactions and further to update the SmPC section 5.2 to include the in vitro data obtained with regard to fidaxomicin and inhibition of OATP2B1, BCRP and MRP2. In addition, section 4.5 of the SmPC is amended, in order to improve readability. The Package Leaflet is updated accordingly. The list of local representatives is updated, to add a representative for Croatia. Furthermore, the PI is being brought in line with the latest QRD template version 9 (and black symbol information requirement is implemented). | 27/06/2013 | 13/12/2013 | SmPC, Annex II and PL | Review of the Phase 3 clinical trial database revealed no significant hypersensitivity reactions that were believed to be related to fidaxomicin. Skin rash was infrequent (2.8%). From the date of first marketing in the U.S., fidaxomicin received five non-serious, medically confirmed reports of potential hypersensitivity reactions (four reports of rash and one report of a burning sensation of the throat, arms, and legs). All reported symptoms were mild and either self-limiting or easily managed with anti-histamines. Hence, the post-marketing database was searched for any events equal to Anaphylactic reaction (SMQ) or Angioedema (SMQ). Two such cases were identified during |

<div style=\"page-break-after: always\"></div>

|             | The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                          |            |     | this reporting period of which one had a positive rechallenge reported. Based on aforementioned information, following assessment of PSUR 1 (covering period 27/11/2011- 26/05/2012), the MAH had been requested to add appropriate warnings and precautions to the SmPC. In addition, as part of Post-Authorisation Measures, two in vitro studies showed that neither fidaxomicin nor OP-1118 are substrates, but both are inhibitors, of transporters BCRP, MRP2, and OATP2B1. A clinical study is planned to evaluate the clinical relevance of these in vitro data. In the meantime, an appropriate statement is introduced in section 5.2 of the SmPC.   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0012/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 06/05/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IAIN/0010   | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                                                                                                                                                          | 18/03/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IAIN/0009/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/02/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|             | C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                        |            |            |                                  |                |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------|
| IAIN/0008/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                              | 11/01/2013 | 13/12/2013 | SmPC, Annex II, Labelling and PL |                |
| IB/0007     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                    | 17/12/2012 | 13/12/2013 | SmPC                             |                |
| IA/0006/G   | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.a - Change to in-process tests or limits the manufacture of the AS - | 10/12/2012 | n/a        |                                  | applied during |

<div style=\"page-break-after: always\"></div>

|             | of in-process limits - Change to in-process tests or limits during the manufacture of the AS - of in-process limits                                                                                                                                                                                                                                                |            |            |                 | Tightening B.I.a.4.a applied Tightening   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------|
| IAIN/0005   | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                                                                                                                                        | 26/10/2012 | n/a        |                 |                                           |
| IAIN/0004/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.b.2 - Change to batch release arrangements and quality control testing of the FP - Including batch | 12/06/2012 | 29/10/2012 | Annex II and PL | control/testing                           |
| IAIN/0003/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site Change to batch release arrangements                                                                        | 04/04/2012 | 27/06/2012 | SmPC            | B.II.b.2.b.2 -                            |

<div style=\"page-break-after: always\"></div>

|           | control testing of the FP - Including batch control/testing A.7 - Administrative change - Deletion of manufacturing sites A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |            |             | and quality   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------|
| IB/0002/G | This was an application for a group of variations. C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant NCA/EMA for another product of the same MAH C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD                                                        | 23/03/2012 | n/a        |             |               |
| T/0001    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/01/2012 | 06/02/2012 | SmPC and PL |               |